The correlation between anti-phospholipase A2 receptor antibodies and hypercoagulability in patients with idiopathic membranous nephropathy

References

• Hoxha E, Reinhard L, Stahl RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022; 18(7):1–8.
   PubMed Web of Science ®Google Scholar
• Beck LH, Bonegio RGB, Lambeau G, et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11–21. doi: 10.1056/NEJMoa0810457. PubMed PMID: 19571279; PubMed Central PMCID: PMC2762083.
   PubMed Web of Science ®Google Scholar
• Kukuy OL, Cohen R, Gilburd B, et al. The prognostic value of anti-PLA2R antibodies levels in primary membranous nephropathy. Int J Mol Sci. 2023;24(10):9051.
   PubMed Web of Science ®Google Scholar
• Radice A, Trezzi B, Maggiore U, et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev. 2016; 15(2):146–154.
   PubMed Web of Science ®Google Scholar
• Li SJ, Guo JZ, Zuo K, et al. Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study. Thromb Res. 2012; 130(3):501–505.
   PubMed Web of Science ®Google Scholar
• Loscalzo J. Venous thrombosis in the nephrotic syndrome. N Engl J Med. 2013; 368(10):956–958.
   PubMed Web of Science ®Google Scholar
• Roca N, Jatem E, Martín ML, et al. Relationship between soluble urokinase-type plasminogen activator receptor and serum biomarkers of endothelial activation in patients with idiopathic nephrotic syndrome. Clin Kidney J. 2021;14(2):543–549.
   PubMed Web of Science ®Google Scholar
• Huang MJ, Wei RB, Wang ZC, et al. Mechanisms of hypercoagulability in nephrotic syndrome associated with membranous nephropathy as assessed by thromboelastography. Thromb Res. 2015;136(3):663–668.
   PubMed Web of Science ®Google Scholar
• Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012; 7(3):513–520.
   PubMed Web of Science ®Google Scholar
• Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118(3):397–407.
   PubMed Web of Science ®Google Scholar
• Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013;173(9):743–752.
   PubMed Web of Science ®Google Scholar
• Simion C, Campello E, Bensi E, et al. Use of glucocorticoids and risk of venous thromboembolism: a narrative review. Semin Thromb Hemost. 2021;47(6):654–661.
   PubMedGoogle Scholar
• Coelho MC, Santos CV, Vieira Neto L, et al. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol. 2015;173(4):M11–21.
   PubMed Web of Science ®Google Scholar
• Gonzalez E, Pieracci FM, Moore EE, et al. Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography. Semin Thromb Hemost. 2010;36(7):723–737.
   PubMed Web of Science ®Google Scholar
• Hamano K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis. 2002;39(4):695–705.
   PubMed Web of Science ®Google Scholar
• Zhu H, Xu L, Liu X, et al. Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy. Ren Fail. 2022; 44(1):594–600.
   PubMed Web of Science ®Google Scholar
• Sirolli V, Ballone E, Garofalo D, et al. Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron. 2002;91(3):424–430.
   PubMed Web of Science ®Google Scholar
• Zwaginga JJ, Koomans HA, Sixma JJ, et al. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest. 1994;93(1):204–211.
   PubMed Web of Science ®Google Scholar
• Mirrakhimov AE, Ali AM, Barbaryan A, et al. Primary nephrotic syndrome in adults as a risk factor for pulmonary embolism: an up-to-date review of the literature. Int J Nephrol. 2014;2014:916760–916769.
   PubMedGoogle Scholar
• Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019;129(1):12–23.
   PubMed Web of Science ®Google Scholar
• Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134(22):1912–1918.
   PubMed Web of Science ®Google Scholar
• Ji Y, Wang YL, Xu F, et al. Elevated soluble podoplanin associates with hypercoagulability in patients with nephrotic syndrome. Clin Appl Thromb Hemost. 2022; 28:10760296221108967.
   Web of Science ®Google Scholar
• Khan SA, Ilies MA. The phospholipase A2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles. Int J Mol Sci. 2023;24(2):1353.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang M, Guo Y, et al. Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy. Clin Chim Acta. 2018;482:178–184.
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Beck LH, Jr., Beck DM, et al. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286–1291.
   PubMed Web of Science ®Google Scholar
• Schieppati A, Dodesini P, Benigni A, et al. The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney Int. 1984;25(4):671–676.
   PubMed Web of Science ®Google Scholar
• Pan Y, Wan J, Liu Y, et al. sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor. Sci Rep. 2014;4(1):6660.
   PubMedGoogle Scholar
• Lu X, Kan C, Zhang R. Phospholipase A2 receptor is associated with hypercoagulable status in membranous nephropathy: a narrative review. Ann Transl Med. 2022;10(17):938–938.
   PubMedGoogle Scholar
• Yang L, Wu Y, Lin S, et al. sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK/mTOR/ULK1(ser757) signaling pathway. Faseb J. 2021;35(2):e21170.
   PubMed Web of Science ®Google Scholar
• Girot R, Jaubert F, Leon M, et al. Albumin, fibrinogen, prothrombin and antithrombin III variations in blood, urines and liver in rat nephrotic syndrome (Heymann nephritis). Thromb Haemost. 1983;49(1):13–17.
   PubMed Web of Science ®Google Scholar
• Asch AS, Leung LL, Polley MJ, et al. Platelet membrane topography: colocalization of thrombospondin and fibrinogen with the glycoprotein IIb-IIIa complex. Blood. 1985;66(4):926–934.
   PubMed Web of Science ®Google Scholar
• Perutelli P, Mori PG. The human platelet membrane glycoprotein IIb/IIIa complex: a multi-functional adhesion receptor. Haematologica. 1992;77(2):162–168.
   PubMed Web of Science ®Google Scholar